I tend to agree with BDAZ and BKC as far as there are positive things going on on the scientific development side which could provide the nearer term inflection points which Don has spoken of. As BKC pointed out markets for treatment of inflammatory diseases are massive and kidney disease is a huge and very expensive disease (once it comes to dialysis/transplant) which is growing at a very scary rate. Look at the American and Canadian kidney foundation websites. I think that Dr K-Z was excited in September with good reason. We could very well see clinical work on this well before the end of BoM. WRT to Hartlands comments regarding the FDA, I also had questions about the animal work/FDA comment so I phoned RVX the next day (something that should perhaps be done more often). I was told that the FDA had requested more animal work wrt RVX-208 + atorvistatin (Lipitor) and that this work is almost complete. I'm not certain that this means that the FDA is out of BoM at all. Of course they would also have to approve of the over all trial design as well if they are happy with the animal work. My biggest complaint about management is and always has been that IMO there is complete lack of understanding of how to properly promote a public company. I think RVX still has one of the best biotech stories out there but I firmly believe that a Canadian company promoting in the US is pretty much a complete waste of time and money without a NAZDAQ listing but I've gone on about this subject before so I won't again.